Health & bio
Pfizer-Valneva Lyme vaccine shows 70-plus percent efficacy in Phase 3
Pfizer and Valneva reported Phase 3 VALOR study efficacy exceeding 70 percent for their Lyme vaccine candidate in ages five and up.
Primary sources · 1
Pfizer and Valneva reported Phase 3 VALOR study efficacy exceeding 70 percent for their Lyme vaccine candidate in ages five and up.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.